Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 10/20 | 0.56 |
| ▸ | GAA | P10253 | 10/20 | 0.56 |
| ▸ | SI | P14410 | 10/20 | 0.56 |
| ▸ | MGAM2 | Q2M2H8 | 10/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MPO | P05164 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2232718 | 1.00 | MGAM (0.56) | MGAMGAASIMGAM2MEN1 | |
| SCHEMBL21690083 | 1.00 | MGAM (0.56) | MGAMGAASIMGAM2MEN1 | |
| Hydrochloric Acid SCHEMBL9332216 | 0.98 | MGAM (0.55) | MGAMGAASIMGAM2MEN1 | |
| SCHEMBL27763691 | 0.88 | MGAM (0.52) | MGAMGAASIMGAM2MEN1 | |
| SCHEMBL14631586 | 0.84 | MGAM (0.49) | MGAMGAASIMGAM2MEN1 | |
| SCHEMBL6288559 | 0.83 | MGAM (0.57) | MGAMGAASIMGAM2MEN1 | |
| SCHEMBL28701362 | 0.82 | HTR2A (0.55) | MGAMGAASIMGAM2MEN1 | |
| SCHEMBL4471722 | 0.81 | PKM (0.59) | MGAMGAASIMGAM2MEN1 | |
| SCHEMBL6982959 | 0.81 | HTR2A (0.62) | MGAMGAASIMGAM2MEN1 | |
| SCHEMBL3656418 | 0.81 | HTR2A (0.62) | MGAMGAASIMGAM2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2113587-B9 | Aqueous acidic bath and method for electroplating copper | ATOTECH DEUTSCHLAND GMBH (DE) | 2011-09-07 | — | — | EP | claimed |
| EP-2113587-B1 | Aqueous acidic bath and method for electroplating copper | ATOTECH DEUTSCHLAND GMBH (DE) | 2011-04-20 | — | — | EP | claimed |
| US-20230203098-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE | JCR PHARMACEUTICALS CO., LTD. (JP) | 2023-06-29 | — | — | US | disclosed |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-20 | — | — | US | disclosed |
| WO-2021067439-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2021-04-01 | — | — | US | disclosed |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RAPAFUSYN PHARMACEUTICALS, INC. | 2020-02-06 | — | — | US | disclosed |
| EP-2694095-B1 | COMPOSITIONS COMPRISING GLUCAGON ANALOGS AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH INC (US) | 2018-03-07 | — | — | EP | disclosed |
| EP-2694095-A1 | COMPOSITIONS COMPRISING GLUCAGON ANALOGS AND METHODS OF MAKING AND USING THE SAME | Longevity Biotech, Inc. (US) | 2014-02-12 | — | — | EP | disclosed |
| WO-2012138941-A1 | COMPOSITIONS COMPRISING GLUCAGON ANALOGS AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. (US) | 2012-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, FKBP14, MTOR | MGAM 1577/4885GAA 1820/4885SI 2087/4885 |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | MGAM 1577/4885GAA 1820/4885SI 2087/4885 |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | MGAM 1577/4885GAA 1820/4885SI 2087/4885 |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | MGAM 1577/4885GAA 1820/4885SI 2087/4885 |
| US-20230203098-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE | TFRC, SLC3A2, SLC7A1 | MGAM 4569/4885GAA 3362/4885SI 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.